HROW Stock Forecast & Price Target

Harrow is well positioned to capitalize on the growing demand for ophthalmic pharmaceuticals in the US market, with a strong portfolio of established and developing products addressing various eye conditions. With a focus on driving growth and expanding through strategic acquisitions, the company has the potential to achieve their long-term goal of $250M in quarterly revenue by 2027. Their successful sales force expansion and acquisition of new products, combined with the utilization of word-of-mouth among physician groups and receipt of a J-Code assignment, further supports their growth strategy. Overall, Harrow's solid financial performance and promising development pipeline make it a promising investment for the future.

Harrow is facing short term challenges with weakened revenue from unexpected high deductible plans negatively impacting Vevye sales in Q1 of 2026. However, the company expects to see growth in the latter half of 2026 with the potential for strong sales due to clinical data showcasing the superior pain and comfort attributes of their key drug IHEEZO, driving revenue and fueling future growth. The loss of pass-through status for IHEEZO in the surgical setting in April also led to distributor stocking and an anticipated price reset which may impact sales in the short term but could ultimately result in higher sales and revenue in the future.